我要投票 白云山在精准医疗行业中的票数:272
· 外 推 电 报 ·
2025-04-02 19:59:39 星期三

【白云山是哪个国家的品牌?】

白云山是什么牌子?「白云山」是 广州白云山医药集团股份有限公司 旗下著名品牌。由创始人李楚源在1997-09-01期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。

外推网助力白云山品牌出海!通过在本页面挂载白云山品牌的产品链接和联系邮箱,可以提高白云山产品曝光!跨境电商爆单神器,目前只要100元/年哦~

广州白云山制药股份有限公司创业于1973年,1992年11月经广州市人民政府批准,由广州白云山制药总厂等五家企业通过改制成立股份制企业,1993年11月作为广州市首批上市公司之一在深圳证券交易所挂牌上市,现拥有总股本4.69亿元。2007年销售规模达36.1亿元,2008年销售规模超过40亿元。

公司多年来致力品牌建设,是最早在国内树立药品制剂品牌的公司之一,其品牌的知名度和美誉度在全国消费者中具有强大的影响力。2006年“白云山”商标被认定为中国驰名商标,2007年被确定为“重点培养和发展的广东省出口名牌”称号,2008年品牌价值被评估为105.2亿元。

在网络建设方面,公司以敢为天下先的勇气,30多年前率先在全国建立自己的营销网络,目前已形成总部带动,辐射全国及亚非的营销网络。

在科技创新方面,公司实行“科技白云山”战略,与一流的科研院校、国内知名研究机构、国际抗生素巨头合作,研制具有世界先进水平的药物。目前拥有药品批文1700多个,有几十个品种的生产销售规模在全国制药行业中处于领先地位,其中,仙力素(头孢硫脒)粉针剂的开发和投产上市,填补了我国自行研制、开发头孢类抗生素的一个空白,并于2007年获得国家技术发明二等奖。公司成立了由刘昌孝院士领衔的华南首家现代中药研究院,该院被国家批准为博士后工作站;成立了由钟南山等五院士领衔的“中医药防治病毒性传染病产学研联盟”,这是目前我国中医药界产生的首个跨领域产学研联合体,形成了国家、省、市三级科技研发体系。

公司始终坚持“爱心满人间”的经营理念,勇于承担社会责任,以关爱健康、奉献爱心为己任,创业以来一直关爱社会弱势群体,孜孜不倦地追求生命健康事业。大灾面前显大爱,从早期的大兴安岭火灾、98洪灾,到近期的非典、南方冰雪灾、汶川地震等等,积极捐款捐药,抗击灾难;为传承中医药文化,建立了“神农草堂”中医药博物馆;公司努力建设“责任白云山、公民白云山”,首创“家庭过期药品回收机制”、“五级质量体系”、首倡“合理用药”;努力推动节能减排、环保和安全生产,获得了“全国重合同守信用”和广东省“清洁生产型企业”、“节水型企业”、“安全文化示范单位”、“客户满意服务明星企业”等多项荣誉。

今后,公司将以专业化做稳,以科学管理做好,以科技创新做强,以资本运营做大。白云山制药将建成高科技含量、高文化附加值、高市场占有率、具有强大竞争力的一流名牌企业。

英文翻译:Guangzhou Baiyunshan Pharmaceutical Co., Ltd. was founded in 1973. In November 1992, it was approved by Guangzhou Municipal People's government. Five enterprises, including Guangzhou Baiyunshan Pharmaceutical General Factory, established joint-stock enterprises through restructuring. In November 1993, it was listed on Shenzhen Stock Exchange as one of the first listed companies in Guangzhou. Now it has a total share capital of 469 million yuan. In 2007, the sales volume reached 3.61 billion yuan, and in 2008, the sales volume exceeded 4 billion yuan. The company has been committed to brand building for many years. It is one of the first companies to establish the brand of pharmaceutical preparations in China. Its brand awareness and reputation have a strong influence on consumers across the country. In 2006, "Baiyunshan" trademark was recognized as a well-known trademark in China, and in 2007 it was identified as the "Guangdong export famous brand with key cultivation and development". In 2008, the brand value was evaluated as 10.52 billion yuan. In terms of network construction, the company takes the courage to be the first in the world. More than 30 years ago, it took the lead in establishing its own marketing network in the country. At present, it has formed a marketing network driven by the headquarters and radiating across the country and Asia and Africa. In terms of scientific and technological innovation, the company implements the strategy of "Baiyun Mountain of science and technology", cooperates with first-class scientific research institutions, domestic well-known research institutions and international antibiotic giants to develop drugs with the world's advanced level. At present, there are more than 1700 drug approvals, and dozens of varieties of production and sales scale are in the leading position in the national pharmaceutical industry. Among them, the development and launch of the injection of xianlisu (cefathiamidine) powder fill a gap in the development and development of cephalosporins in China, and won the second prize of national technological invention in 2007. The company has established the first modern Chinese Medicine Research Institute in South China led by academician Liu Changxiao, which has been approved as a postdoctoral workstation by the state; established the "industry university research alliance of Chinese medicine for the prevention and treatment of viral infectious diseases" led by academician Zhong Nanshan and other five academicians, which is the first interdisciplinary Industry University Research Association of Chinese medicine industry in China, forming a three-level scientific and technological research and development system at the national, provincial and municipal levels 。 The company always adheres to the business philosophy of "love is all over the world", has the courage to bear social responsibility, takes care of health and dedication of love as its own responsibility, and has been caring for the vulnerable groups in society since its establishment, and has been tirelessly pursuing life and health undertakings. Great love was shown in front of the disaster, from the early Daxinganling fire and 98 Flood, to the recent SARS, ice and snow disaster in the south, Wenchuan earthquake and so on, and actively donated medicine to fight against the disaster; in order to inherit the traditional Chinese medicine culture, the "Shennong Caotang" Museum of traditional Chinese medicine was established; the company made great efforts to establish "responsible Baiyun Mountain, citizen Baiyun Mountain", and the first "family overdue medicine recovery mechanism"“ Five level quality system, the first initiative of "rational use of drugs"; efforts to promote energy conservation and emission reduction, environmental protection and safety in production, won many honors such as "national contract abiding and trustworthy" and "clean production enterprise", "water-saving enterprise", "safety culture demonstration unit", "star enterprise of customer satisfaction service" in Guangdong Province. In the future, the company will do well in specialization, scientific management, scientific innovation and capital operation. Baiyunshan Pharmaceutical will become a first-class famous brand enterprise with high-tech content, high cultural added value, high market share and strong competitiveness.

本文链接: https://www.waitui.com/brand/24e921532.html 联系电话:请联系客服添加

千城特选小程序码

7×24h 快讯

今年一季度A股新开户747万户,同比增长31.74%

36氪获悉,4月2日,上交所披露,今年3月A股新开户数据306.55万户,环比继续快速增长。数据显示,今年1月、2月和3月A股新开户数分别为157万户、283.59万户和306.55万户。今年3月新增开户数306.55万户,较2024年3月新开户数242万户同比增长26.67%。

2小时前

国信证券:获批发行不超200亿元永续次级债券

36氪获悉,国信证券公告,近日收到中国证监会出具的批复,同意公司向专业投资者公开发行面值总额不超过200亿元永续次级债券的注册申请。批复自同意注册之日起24个月内有效,公司在注册有效期内可以分期发行永续次级公司债券。公司将按照有关法律法规和上述批复文件要求及公司股东大会的授权办理永续次级债券发行的相关事宜,并及时履行信息披露义务。

2小时前

华为哈勃入股成都芯曌科技,后者含电子专用材料研发等业务

36氪获悉,天眼查App显示,近日,成都芯曌科技有限公司发生工商变更,新增华为旗下深圳哈勃科技投资合伙企业(有限合伙)为股东,注册资本由6213万人民币增至约7020万人民币,同时,部分高管发生变更。成都芯曌科技有限公司成立于2019年10月,法定代表人为朱荣,经营范围含电子专用材料研发、电子专用材料制造、电子专用材料销售、集成电路设计、电子元器件制造等。股东信息显示,该公司现由成都大超科技有限公司、朱荣及上述新增股东共同持股。

2小时前

恒润股份:公司基本面未发生重大变化

36氪获悉,恒润股份发布股票交易风险提示公告,公司股票股价短期涨幅较大,存在一定风险。公司基本面未发生重大变化,也不存在应披露而未披露的重大信息。敬请广大投资者注意二级市场交易风险,理性决策,审慎投资。

2小时前

立讯精密被曝正考虑赴港上市?官方不予置评

日前,有消息称,有知情人士透露立讯精密考虑今年在香港上市,目前正与投行商讨赴港上市事宜,初步预计融资规模为20亿至30亿美元。不过,知情人士也提醒,立讯精密赴港上市规模尚未最终确定,将取决于市场情况。对此,立讯精密表示,不予置评。

2小时前

本页详细列出关于康圣环球的品牌信息,含品牌所属公司介绍,康圣环球所处行业的品牌地位及优势。
咨询